Interleukin-4 modulates type I interferon to augment anti-tumour immunity
RNA-seq (gene expression) · mouse · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 30 samples: 10 × B16-GFP Tumours (Day 8) biol vs 10 × B16-IFNA4 Tumours (Day 8) biol vs 10 × B16-IFNA9 Tumours (Day 8) biolGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Interleukin-4 modulates type I interferon to augment antitumor immunityScience advances · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE289722_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1224251 and SRA study SRP564164. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 3 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8797517 B16-GFP Tumours (Day 8) biol rep 1 B16-GFP Tumours (Day 8)…
- GSM8797518 B16-GFP Tumours (Day 8) biol rep 2 B16-GFP Tumours (Day 8)…
- GSM8797519 B16-GFP Tumours (Day 8) biol rep 3 B16-GFP Tumours (Day 8)…
- GSM8797520 B16-GFP Tumours (Day 8) biol rep 4 B16-GFP Tumours (Day 8)…
- GSM8797521 B16-GFP Tumours (Day 8) biol rep 5 B16-GFP Tumours (Day 8)…
- GSM8797522 B16-GFP Tumours (Day 8) biol rep 6 B16-GFP Tumours (Day 8)…
- GSM8797523 B16-GFP Tumours (Day 8) biol rep 7 B16-GFP Tumours (Day 8)…
- GSM8797524 B16-GFP Tumours (Day 8) biol rep 8 B16-GFP Tumours (Day 8)…
- GSM8797525 B16-GFP Tumours (Day 8) biol rep 9 B16-GFP Tumours (Day 8)…
- GSM8797526 B16-GFP Tumours (Day 8) biol rep 10 B16-GFP Tumours (Day 8)…
- GSM8797527 B16-IFNA4 Tumours (Day 8) biol rep 1 B16-IFNA4 Tumours (Day …
- GSM8797528 B16-IFNA4 Tumours (Day 8) biol rep 2 B16-IFNA4 Tumours (Day …
- GSM8797529 B16-IFNA4 Tumours (Day 8) biol rep 3 B16-IFNA4 Tumours (Day …
- GSM8797530 B16-IFNA4 Tumours (Day 8) biol rep 4 B16-IFNA4 Tumours (Day …
- GSM8797531 B16-IFNA4 Tumours (Day 8) biol rep 5 B16-IFNA4 Tumours (Day …
- GSM8797532 B16-IFNA4 Tumours (Day 8) biol rep 6 B16-IFNA4 Tumours (Day …
- GSM8797533 B16-IFNA4 Tumours (Day 8) biol rep 7 B16-IFNA4 Tumours (Day …
- GSM8797534 B16-IFNA4 Tumours (Day 8) biol rep 8 B16-IFNA4 Tumours (Day …
- GSM8797535 B16-IFNA4 Tumours (Day 8) biol rep 9 B16-IFNA4 Tumours (Day …
- GSM8797536 B16-IFNA4 Tumours (Day 8) biol rep 10 B16-IFNA4 Tumours (Day …
- GSM8797537 B16-IFNA9 Tumours (Day 8) biol rep 1 B16-IFNA9 Tumours (Day …
- GSM8797538 B16-IFNA9 Tumours (Day 8) biol rep 2 B16-IFNA9 Tumours (Day …
- GSM8797539 B16-IFNA9 Tumours (Day 8) biol rep 3 B16-IFNA9 Tumours (Day …
- GSM8797540 B16-IFNA9 Tumours (Day 8) biol rep 4 B16-IFNA9 Tumours (Day …
- GSM8797541 B16-IFNA9 Tumours (Day 8) biol rep 5 B16-IFNA9 Tumours (Day …
- GSM8797542 B16-IFNA9 Tumours (Day 8) biol rep 6 B16-IFNA9 Tumours (Day …
- GSM8797543 B16-IFNA9 Tumours (Day 8) biol rep 7 B16-IFNA9 Tumours (Day …
- GSM8797544 B16-IFNA9 Tumours (Day 8) biol rep 8 B16-IFNA9 Tumours (Day …
- GSM8797545 B16-IFNA9 Tumours (Day 8) biol rep 9 B16-IFNA9 Tumours (Day …
- GSM8797546 B16-IFNA9 Tumours (Day 8) biol rep 10 B16-IFNA9 Tumours (Day …
- GSE289723 Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq] 36 samples shares interleukin-4, anti-tumour, interferon, modulates, immunity, augment, type
- GSE295483 Type-I interferon priming signal balances anti-bacterial and anti-tumor trained immunity in alveolar macrophages [RNA-seq] 19 samples shares interferon, immunity, type
- GSE217807 ARID1A suppresses R-loop mediated STING-Type I Interferon pathway activation of anti-tumor immunity 62 samples shares interferon, immunity, type
- GSE317032 Non-cytolytic viral vaccine vectors induce durable effector-memory CD8 T cell immunity by triggering type I interferon 18 samples shares interferon, immunity, type
- GSE297709 STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity 18 samples shares interferon, immunity, type
- GSE285518 Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon responses via MYC/CDK2/DNMT1 pathway. 18 samples shares interferon, immunity, type
- GSE287098 Influenza virus-induced type I interferons disrupt alveolar epithelial repair and tight junction integrity in the developing lung 96 samples shares interferon, type
- GSE304521 SEX-DEPENDENT TYPE I INTERFERON SIGNALING EXACERBATES ALZHEIMER'S PATHOLOGY 82 samples shares interferon, type
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.